Liquid chromatography/mass spectrometry (LC/MS)-based glycoproteomics technologies for cancer biomarker discovery

被引：0
作者：
Kaji H. [1 ,2 ]
Isobe T. [2 ,3 ]
机构：
[1] Glycoproteomics Team, Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8568, Central 2
[2] Department of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, Tokyo 192-0397
[3] CREST, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012
来源：
Clinical Proteomics | 2008年 / 4卷 / 1-2期
关键词：
Biomarker; Cancer; Glycoproteins; Glycoproteomics; Liquid chromatography; Mass spectrometry; Proteome;
D O I：
10.1007/s12014-008-9004-1
中图分类号：
学科分类号：
摘要：
Introduction: Biomarker discovery is a major objective of clinical proteomics; molecular biomarkers allow for detection of early-stage human diseases, especially cancer, and for monitoring their progression and/or regression after treatment. Biomarkers also help to elucidate the pathology of disease and its diagnosis, drug discovery, and toxicology. Glycans are ideal candidates for biomarkers because (1) glycoconjugates are localized on the cell surface and in the secretions such as plasma, (2) their structures are frequently and drastically changed during normal and aberrant cell differentiation, and (3) different cell types express different glycan signatures. Certain serodiagnostic glycoconjugate markers, such as carcinoembryonic antigen (CEA), are currently available; however, comprehensive glycome analysis has yet to be performed, mainly because of the difficulties of isolating and structurally analyzing complex glycans. Large-scale glycoprotein analysis, termed glycoproteomics, has the potential to effectively trace cellular glycoproteins and therefore to search for new serodiagnostic biomarkers. Conclusions: In this review, we describe current mass spectrometry-based glycoproteomics technologies. Quantitative "shotgun" proteomics analyses of glycopeptides captured from complex biological mixtures such as plasma, coupled with advanced glycome technologies, enhance our knowledge of protein glycosylation and facilitate discovery of new biomarkers for human diseases. © 2008 Humana Press.
引用
收藏
页码：14 / 24
页数：10
相关论文
共 97 条
[1]  
Ahn S.M., Simpson R.J., Body fluid proteomics: Prospects for biomarker discovery, Proteomics Clin Appl., 1, pp. 1004-15, (2007)
[2]  
Zafir-Lavie I., Michaeli Y., Reiter Y., Novel antibodies as anticancer agents, Oncogene., 26, pp. 3714-33, (2007)
[3]  
Greengauz-Roberts O., Stoppler H., Nomura S., Yamaguchi H., Goldenring J.R., Podolsky R.H., Lee J.R., Dynan W.S., Saturation labeling with cysteine-reactive cyanine fluorescent dyes provides increased sensitivity for protein expression profiling of laser-microdissected clinical specimens, Proteomics., 5, pp. 1746-57, (2005)
[4]  
Kondo T., Hirohashi S., Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics, Nat Protoc., 1, pp. 2940-56, (2006)
[5]  
Espina V., Heiby M., Pierobon M., Liotta L.A., Laser capture microdissection technology, Expert Rev Mol Diagn., 7, pp. 647-57, (2007)
[6]  
Hu S., Loo J.A., Wong D.T., Human body fluid proteome analysis, Proteomics., 6, pp. 6326-53, (2006)
[7]  
Lee H.J., Lee E.Y., Kwon M.S., Paik Y.K., Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics, Curr Opin Chem Biol., 10, pp. 42-9, (2006)
[8]  
Hoffman S.A., Joo W.A., Echan L.A., Speicher D.W., Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma, J Chromatogr B Analyt Technol Biomed Life Sci., 849, pp. 43-2, (2007)
[9]  
Anderson N.L., Polanski M., Pieper R., Gatlin T., Tirumalai R.S., Conrads T.P., Veenstra T.D., Adkins J.N., Pounds J.G., Fagan R., Lobley A., The human plasma proteome: A nonredundant list developed by combination of four separate sources, Mol Cell Proteomics., 3, pp. 311-26, (2004)
[10]  
Schulenberg B., Beechem J.M., Patton W.F., Mapping glycosylation changes related to cancer using the multiplexed proteomics technology: A protein differential display approach, J Chromatogr B Analyt Technol Biomed Life Sci., 793, pp. 127-39, (2003)
12345678910